Evaxion Biotech AS has a consensus price target of $10 based on the ratings of 4 analysts. The high is $14 issued by HC Wainwright & Co. on June 4, 2024. The low is $7 issued by Lake Street on March 31, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and Ladenburg Thalmann on June 4, 2024, April 3, 2024, and April 2, 2024, respectively. With an average price target of $12 between HC Wainwright & Co., HC Wainwright & Co., and Ladenburg Thalmann, there's an implied 312.37% upside for Evaxion Biotech AS from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/04/2024 | Buy Now | 381.1% | HC Wainwright & Co. | Swayampakula Ramakanth | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
04/03/2024 | Buy Now | 381.1% | HC Wainwright & Co. | Swayampakula Ramakanth | → $14 | Reiterates | Buy → Buy | Get Alert |
04/02/2024 | Buy Now | 174.91% | Ladenburg Thalmann | Ahu Demir | → $8 | Upgrade | Neutral → Buy | Get Alert |
03/20/2024 | Buy Now | 381.1% | HC Wainwright & Co. | Swayampakula Ramakanth | → $14 | Reiterates | Buy → Buy | Get Alert |
02/12/2024 | Buy Now | 381.1% | HC Wainwright & Co. | Swayampakula Ramakanth | → $14 | Initiates | → Buy | Get Alert |
12/21/2023 | Buy Now | — | Ladenburg Thalmann | Ahu Demir | — | Downgrade | Buy → Neutral | Get Alert |
03/31/2023 | Buy Now | 140.55% | Lake Street | Thomas Flaten | $180 → $70 | Maintains | Buy | Get Alert |
11/17/2022 | Buy Now | 278.01% | Oppenheimer | Jeff Jones | $160 → $110 | Maintains | Outperform | Get Alert |
07/18/2022 | Buy Now | 449.83% | Oppenheimer | Jeff Jones | → $160 | Assumes | → Outperform | Get Alert |
The latest price target for Evaxion Biotech (NASDAQ:EVAX) was reported by HC Wainwright & Co. on June 4, 2024. The analyst firm set a price target for $14.00 expecting EVAX to rise to within 12 months (a possible 364.01% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Evaxion Biotech (NASDAQ:EVAX) was provided by HC Wainwright & Co., and Evaxion Biotech reiterated their buy rating.
The last upgrade for Evaxion Biotech AS happened on April 2, 2024 when Ladenburg Thalmann raised their price target to $8. Ladenburg Thalmann previously had a neutral for Evaxion Biotech AS.
The last downgrade for Evaxion Biotech AS happened on December 21, 2023 when Ladenburg Thalmann changed their price target from N/A to N/A for Evaxion Biotech AS.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evaxion Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evaxion Biotech was filed on June 4, 2024 so you should expect the next rating to be made available sometime around June 4, 2025.
While ratings are subjective and will change, the latest Evaxion Biotech (EVAX) rating was a reiterated with a price target of $14.00 to $14.00. The current price Evaxion Biotech (EVAX) is trading at is $3.02, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.